2021
Thematic Series
Sepsis - what's in the discovery pipeline?
2020
Thematic Series
Gaseous Mediators: Potential application in Critical Care
Thematic Series
COVID-19
An official journal of the European Society of Intensive Care Medicine (ESICM)
Members should contact members@esicm.org for a 40% discount on the article-proccessing charge.
Articles
-
-
Plasma hyaluronan, hyaluronidase activity and endogenous hyaluronidase inhibition in sepsis: an experimental and clinical cohort study
-
ESICM LIVES 2021: Part 2
-
Computed tomographic assessment of lung aeration at different positive end-expiratory pressures in a porcine model of intra-abdominal hypertension and lung injury
-
ESICM LIVES 2021: Part 1
-
Volume 10
Back to top-
ESICM LIVES 2021 - Part 2
Volume 10 Supplement 1
-
-
Volume 9
Back to top-
ESICM LIVES 2021
Volume 9 Supplement 1
-
-
Volume 8
Back to top-
ESICM LIVES 2020
Volume 8 Supplement 2
-
-
Volume 7
Back to top-
ESICM LIVES 2019
Volume 7 Supplement 3
-
Sepsis 2019
Volume 7 Supplement 2
-
-
Volume 6
Back to top-
ESICM LIVES 2018
Volume 6 Supplement 2
-
Sepsis 2018
Volume 6 Supplement 1
-
-
Volume 5
Back to top-
ESICM LIVES 2017
Volume 5 Supplement 2
-
Sepsis 2017 Paris
Volume 5 Supplement 1
-
-
Volume 4
Back to top-
ESICM LIVES 2016
Volume 4 Supplement 1
-
-
Volume 3
Back to top-
ESICM LIVES 2015
Volume 3 Supplement 1
-
-
Volume 2
Back to top-
ESICM LIVES 2014
Volume 2 Supplement 1
-
New in the pipeline
Highly accessed papers 2020
Fluids in ARDS: more pros than cons
Pedro L. Silva, et al.
Review 18 December 2020
Method of respiratory rate measurement using a unique wearable platform and an adaptive optical-based approach
Gurpreet Singh, et al.
Research 24 May 2020
Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials
Waleed Alhazzani, et al. for the GUIDE Group
Review 23 October 2020
COVID-19 and VILI: developing a mobile app for measurement of mechanical power at a glance
Angelo Senzi, et al.
Letters to the Editor 09 February 2021
In vitro characterization of PrismaLung+: a novel ECCO2R device
Markus Storr, et al.
Research 13 May 2020
Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis
Lindsay M. Busch, et al.
Research 04 February 2020
The conundrum of using hyperoxia in COVID-19 treatment strategies: may intermittent therapeutic hyperoxia play a helpful role in the expression of the surface receptors ACE2 and Furin in lung tissue via triggering of HIF-1α?
Andreas Koch, et al.
Hypothesis 15 September 2020
Pathophysiology and clinical consequences of arterial blood gases and pH after cardiac arrest
Chiara Robba, et al.
Review 18 December 2020
Carbon monoxide in intensive care medicine - time to start the therapeutic application?!
Ulrich Goebel & Jakob Wollborn
Review 09 January 2020
Real-time effects of PEEP and tidal volume on regional ventilation and perfusion in experimental lung injury
João Batista Borges, Federico Formenti, et al.
Research 21 February 2020
Emerging pharmacological tools to control hydrogen sulfide signaling in critical illness
Eizo Marutani & Fumito Ichinose
Review 31 January 2020
Heart failure supported by veno-arterial extracorporeal membrane oxygenation (ECMO): a systematic review of pre-clinical models
Sacha Rozencwajg, Jacky Suen, et al. on behalf of the European Extracorporeal Life Support Organisation (EuroELSO) Innovations Workgroup & the National Health Medical Research Council Australia Centre of Research Excellence for Advanced Cardio-respiratory Therapies Improving Organ Support (NHMRC CREACTIONS)
Review 25 May 2020
Use of the CytoSorb adsorption device in MDMA intoxication: a first-in-man application and in vitro study
Corinna N. Lang, Achim Lother, et al.
Research 15 June 2020
The surviving sepsis campaign: basic/translational science research priorities
Clifford S. Deutschman, et al. for the Research Committee of the Surviving Sepsis Campaign
Consensus document 17 July 2020
The effect of positive end-expiratory pressure on cardiac output and oxygen delivery during cardiopulmonary resuscitation
Yosef Levenbrown, et al.
Research 25 July 2020
ESICM meeting abstracts
Article-processing charges
Intensive Care Medicine Experimental levies an article-processing charge of £1570/$2290/€1870 for each article accepted for publication. For information on waivers and discounts, please visit our article-processing charge page.
Intensive Care Medicine
Aims and scope
Intensive Care Medicine Experimental (ICMx) is an open access journal specifically dedicated to translational research, aimed at bringing discoveries, potential novel treatments and improved diagnostics closer to the bedside of a critically ill patient. As such, ICMx is uniquely positioned at the intersection of clinical and basic science with a primary focus on critical care medicine. ICMx is intended for all those involved in research aimed at improving care of the critically ill.
ICMx aims at publishing research aspiring to: 1) advance understanding of mechanisms of critical illness, 2) support or enhance clinical trial design, 3) test experimental novel treatment interventions, 4) develop or refine experimental models that are relevant to critical care conditions.
ICMx welcomes original studies, reviews, hypothesis papers and state-of-the-art methodology papers. We also encourage correspondence pertinent to the works published in ICMx. Editorial comments will be solicited.
- ICMx is the official journal of the European Society of Intensive Care Medicine that is dedicated to translational research
- ICMx is one of few journals publishing research constructing the pipeline of novel discoveries that can advance critical care
- The board of ICMx represents both basic scientists dedicated to ICU medicine and ICU physicians, providing for an ideal platform to bring discoveries to clinical applications in critical care
Nicole Juffermans, Editor-in-Chief
University of Amsterdam, The Netherlands
Find us on Facebook
Official journal of
Follow
Annual Journal Metrics
-
Speed
42 days to first decision for reviewed manuscripts only
35 days to first decision for all manuscripts
76 days from submission to acceptance
56 days from acceptance to publication
Usage
363,600 Downloads
229 Altmetric Mentions
- ISSN: 2197-425X (electronic)